Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LHX stock price vs INCY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INCY's multiple
Needs INCY P/E.
Implied fair value · at LHX's multiple
Needs LHX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
L3HARRIS TECHNOLOGIES, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
INCYTE CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LOCKHEED MARTIN CORP
LHX vs LMT
NORTHROP GRUMMAN CORP /DE/
LHX vs NOC
BOEING CO
LHX vs BA
RTX Corp
LHX vs RTX
GENERAL DYNAMICS CORP
LHX vs GD
HEICO CORP
LHX vs HEI
AMGEN INC
LHX vs AMGN
GILEAD SCIENCES, INC.
LHX vs GILD
VERTEX PHARMACEUTICALS INC / MA
LHX vs VRTX
REGENERON PHARMACEUTICALS, INC.
LHX vs REGN
BIOGEN INC.
LHX vs BIIB
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LHX can sustain above-benchmark earnings growth and justify a materially higher multiple than both its DCF range and INCY-implied value, then hold or only accumulate on weakness; otherwise, reduce exposure because the current price embeds a premium that is not supported by the provided valuation outputs.
LHX trades at $277.06 versus an implied P/E value of $159.05, implying -42.6% downside and a clear valuation premium on this framework. The current price also sits above the historical band midpoint and above the top of the DCF range, suggesting the market is already discounting a stronger outlook than the provided valuation ranges support.
Supporting Metrics
